Narinder Singh
Chief Tech/Sci/R&D Officer at ARCELLX, INC.
Profile
Narinder Singh is currently the Chief Technology Officer at Arcellx, Inc. He previously worked as the VP-Drug Product Development & Manufacturing at Momenta Pharmaceuticals, Inc. from 2015 to 2018, and as the Senior VP-Pharmaceutical Sciences & Manufacturing at Genocea Biosciences, Inc. from 2018 to 2020.
From 2020 to 2021, he was the Head-Technical Operations at Aimmune Therapeutics, Inc. He also briefly served as the Chief Technology Officer at Forte Biosciences, Inc. in 2021.
Mr. Singh received his undergraduate and graduate degrees from the Indian Institute of Technology New Delhi in 1994 and 1995, respectively.
He also received a graduate degree from the University of Houston in 1997 and an MBA from UCLA Anderson School of Management in 2004.
Narinder Singh active positions
| Companies | Position | Start |
|---|---|---|
| ARCELLX, INC. | Chief Tech/Sci/R&D Officer | 2021-09-30 |
Former positions of Narinder Singh
| Companies | Position | End |
|---|---|---|
| FORTE BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2021-09-30 |
| AIMMUNE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-06-30 |
| GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 2020-06-30 |
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2018-02-28 |
Training of Narinder Singh
| University of Houston | Graduate Degree |
| Indian Institute of Technology New Delhi | Graduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| ARCELLX, INC. | Health Technology |
| FORTE BIOSCIENCES, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
- Stock Market
- Insiders
- Narinder Singh
